ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer

Trial Profile

ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
    • 08 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top